Word

ADLIB

Status

Registered

Status Code

707

Status Date

Saturday, June 10, 2023

Serial Number

79169309

Registration Number

5139363

Registration Date

Tuesday, February 14, 2017

Mark Type

4000

Filing Date

Tuesday, April 28, 2015

Published for Opposition

Tuesday, November 29, 2016

Trademark Owner History

Chiome Bioscience Inc. - Original Registrant

Classifications

5 [ Monoclonal antibodies for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]

42 [ Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ] * Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; ] research and development in the field of biotechnology; pharmaceutical research and development; [ conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; ] technical project studies in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; research and development of new products for others [ ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals * ]

In the statement, "the entire class 042" should be deleted, and Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals should be inserted.

Trademark Events

Apr 1, 2024

Partial Invalidation Processed By The Ib

Feb 26, 2024

Partial Invalidation Of Reg Ext Protection Sent To Ib

Feb 26, 2024

Invalidation Processed

Feb 10, 2024

Partial Invalidation Of Reg Ext Protection Created

Jun 10, 2023

Notice Of Acceptance Of Sec. 71 - E-Mailed

Jun 10, 2023

Registered - Partial Sec 71 Accepted

May 29, 2023

Case Assigned To Post Registration Paralegal

Nov 15, 2022

Teas Section 71 Received

Feb 14, 2022

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Mar 7, 2018

Invalidation Reviewed - No Action Required By Office

Feb 23, 2018

Partial Invalidation Of Reg Ext Protection Created

Oct 28, 2017

Final Decision Transaction Processed By Ib

Sep 15, 2017

Final Disposition Notice Sent To Ib

Sep 15, 2017

Final Disposition Processed

Aug 4, 2017

Notification Of Possible Opposition - Processed By Ib

Jun 23, 2017

Correction Under Section 7 - Processed

Jun 6, 2017

Assigned To Paralegal

May 14, 2017

Final Disposition Notice Created, To Be Sent To Ib

Mar 9, 2017

Teas Section 7 Request Received

Feb 14, 2017

Registered-Principal Register

Feb 1, 2017

Applicant Supplied Changes/Corrections After Pub Approval Not Ent

Jan 31, 2017

Assigned To Petition Staff

Dec 28, 2016

Notification Of Possible Opposition Sent To Ib

Dec 28, 2016

Notification Of Possible Opposition Created, To Be Sent To Ib

Dec 16, 2016

Notification Of Possible Opposition - Processed By Ib

Dec 16, 2016

Teas Post Publication Amendment Received

Nov 29, 2016

Official Gazette Publication Confirmation E-Mailed

Nov 29, 2016

Published For Opposition

Nov 9, 2016

Notification Of Possible Opposition Sent To Ib

Nov 9, 2016

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Nov 9, 2016

Notification Of Notice Of Publication E-Mailed

Oct 27, 2016

Law Office Publication Review Completed

Oct 13, 2016

Approved For Pub - Principal Register

Sep 24, 2016

Teas/Email Correspondence Entered

Sep 23, 2016

Correspondence Received In Law Office

Sep 23, 2016

Teas Response To Suspension Inquiry Received

Sep 19, 2016

Suspension Checked - To Attorney For Action

Sep 15, 2016

Assigned To Lie

Mar 10, 2016

Notification Of Letter Of Suspension E-Mailed

Mar 10, 2016

Letter Of Suspension E-Mailed

Mar 10, 2016

Suspension Letter Written

Feb 16, 2016

Teas/Email Correspondence Entered

Feb 15, 2016

Correspondence Received In Law Office

Feb 15, 2016

Teas Response To Office Action Received

Feb 15, 2016

Attorney/Dom.Rep.Revoked And/Or Appointed

Feb 15, 2016

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Sep 4, 2015

Refusal Processed By Ib

Aug 14, 2015

Non-Final Action Mailed - Refusal Sent To Ib

Aug 14, 2015

Refusal Processed By Mpu

Aug 14, 2015

Non-Final Action (Ib Refusal) Prepared For Review

Aug 13, 2015

Non-Final Action Written

Aug 8, 2015

Assigned To Examiner

Jul 29, 2015

Application Filing Receipt Mailed

Jul 25, 2015

New Application Office Supplied Data Entered

Jul 23, 2015

Sn Assigned For Sect 66a Appl From Ib